ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$5.24
+8.71% today
Updated 2026-05-08
Market cap
$1.54B
P/E ratio
—
P/S ratio
19.58x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$2 – $7
Volume
4.7M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
7.3
Growth
B+8.5
Quality
A2.0
Profitability
F6.7
Valuation
B4/9
Piotroski F-Score
Moderate
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →194 stocks currently score above 75
Price targets
Analyst target
$9.14
+74.43%
12-Month target
—
—
Intrinsic (DCF)
$8.88
Margin of safety
+64.75%
1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 788.00% QoQ
+ 64.75% below intrinsic value
+ Debt/equity 0.15x — low leverage
Risks
- Thin margins at -194.90%
- Negative free cash flow $-44.59M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $485.42M | $38.02M | $28.83M | $75.13M | $75.13M |
| Net income | $158.52M | $-146.40M | $-162.86M | $-146.41M | $-8.95M |
| EPS | — | — | — | — | $-0.49 |
| Free cash flow | $204.70M | $-121.38M | $-186.95M | $-174.07M | $-44.59M |
| Profit margin | 32.66% | -385.00% | -564.83% | -194.88% | -194.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-27 | THERMOPYLAE, HOLDINGS LTD. | Buy | 38,000 | $3.44 |
| 2026-02-27 | BOOTH, ANDREW | Buy | 42,600 | $3.42 |
| 2026-02-26 | THERMOPYLAE, HOLDINGS LTD. | Buy | 177,457 | $3.27 |
Peer comparison
Smart narrative
Abcellera Biologics Inc trades at $5.24. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.42, it sits in the grey zone. TTM revenue stands at $75.13M. with profit margins at -194.90%. Our DCF model estimates intrinsic value at $8.88.
Frequently asked questions
What is Abcellera Biologics Inc's stock price?
Abcellera Biologics Inc (ABCL) trades at $5.24.
Is Abcellera Biologics Inc overvalued?
Smart Value Score 41/100 (Grade D, Sell). DCF value $8.88.
What is the price target of Abcellera Biologics Inc (ABCL)?
The analyst target price is $9.14, representing +74.4% upside from the current price of $5.24.
What is the intrinsic value of Abcellera Biologics Inc (ABCL)?
Based on our DCF model, intrinsic value is $8.88, a +64.8% margin of safety versus $5.24.
What is Abcellera Biologics Inc's revenue?
TTM revenue is $75.13M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
2.42 — grey zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio19.58x
ROE-14.50%
Beta1.03
50D MA$3.72
200D MA$4.14
Shares out0.31B
Float0.21B
Short ratio—
Avg volume4.7M
Performance
1 week+4.78%
1 month-5.39%
3 months+2.63%
YTD+2.63%
1 year—
3 years—
5 years—